Our results demonstrated that administering CX4945 either before or after anti‐PD‐1 therapy effectively inhibited tumor progression (with no significant differences among the three groups), alleviated CD8+ T cell exhaustion, and enhanced CD8+ T cell effector functions (Figure S7A–E, Supporting Information). This evidence concerns the gene CD8A and neoplasm.